Novartis and venture capital firm Versant have set up a new biotech – Borealis Biosciences – using a similar model to their earlier alliance to create Chinook Therapeutics.
Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in
Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f